-
Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib
•
US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa Kirin Co., Ltd. (TYO: 4151), granting Kyowa Kirin exclusive commercialization rights to Kura’s menin inhibitor ziftomenib outside of the United States. Kura retains the corresponding rights within the US. Financial Terms and MilestonesAccording to the…
-
Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus
•
Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of its business strategy in the Asia-Pacific (APAC) region. The company is exiting the China market by selling its operations and out-licensing its portfolio commercialization in other APAC territories to partner companies, retaining rights to only…
-
Kyowa Kirin’s Evocalcet Wins NMPA Nod for Chronic Kidney Disease Treatment
•
Kyowa Kirin Co. (TYO: 4151), a Japanese pharmaceutical firm, has secured marketing approval from China’s National Medical Products Administration (NMPA) for its novel drug evocalcet. The drug is indicated for the treatment of secondary hyperparathyroidism (SHPT) in patients undergoing maintenance dialysis due to chronic kidney disease (CKD). Evocalcet, classified as…
-
Kyowa Kirin to Invest $530 Million in US Biologics Factory for Rare Disease Therapies
•
Japanese pharmaceutical company Kyowa Kirin (TYO: 4151) has unveiled plans for a substantial investment of $530 million to construct a state-of-the-art biologics manufacturing facility in the United States. This strategic move is aimed at advancing the development and production of next-generation antibody therapies targeting rare and serious diseases. The facility,…
